skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal Impairment

Arthritis & rheumatology (Hoboken, N.J.), 2016-08, Vol.68 (8), p.2035-2043 [Peer Reviewed Journal]

2016, American College of Rheumatology ;2016, American College of Rheumatology. ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39654 ;PMID: 26894653

Full text available

Citations Cited by
  • Title:
    Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal Impairment
  • Author: Saag, Kenneth G. ; Whelton, Andrew ; Becker, Michael A. ; MacDonald, Patricia ; Hunt, Barbara ; Gunawardhana, Lhanoo
  • Subjects: Adult ; Aged ; Aged, 80 and over ; Double-Blind Method ; Febuxostat - therapeutic use ; Female ; Glomerular Filtration Rate - drug effects ; Gout - complications ; Gout - drug therapy ; Gout Suppressants - therapeutic use ; Humans ; Male ; Middle Aged ; Prospective Studies ; Renal Insufficiency - complications ; Renal Insufficiency - physiopathology ; Rheumatism ; Severity of Illness Index
  • Is Part Of: Arthritis & rheumatology (Hoboken, N.J.), 2016-08, Vol.68 (8), p.2035-2043
  • Description: Objective Renal impairment is a risk factor for gout and a barrier to optimal gout management. We undertook this exploratory study to obtain data that have been heretofore limited regarding the safety and efficacy of febuxostat in patients with moderate‐to‐severe renal impairment (estimated glomerular filtration rate [GFR] 15–50 ml/minute/1.73 m2). Methods Ninety‐six gout patients with moderate‐to‐severe renal impairment were enrolled in a 12‐month multicenter, randomized, double‐blind, placebo‐controlled study. Patients were randomly assigned at a 1:1:1 ratio to receive 30 mg febuxostat twice daily, 40/80 mg febuxostat once daily, or placebo. The primary efficacy end point was the change in serum creatinine (Cr) level from baseline to month 12. Secondary end points included the change in estimated GFR from baseline to month 12 and the proportion of patients with a serum uric acid (UA) level of <6.0 mg/dl at month 12. Results At month 12, there were no significant differences in the change in serum Cr level from baseline, or in the change in estimated GFR from baseline, in either febuxostat group compared to the placebo group. The proportion of patients with a serum UA level of <6.0 mg/dl at month 12 was significantly greater in both febuxostat groups compared to the placebo group (both P < 0.001). At least 1 treatment‐emergent adverse event (TEAE) occurred in 78.1% of patients receiving 30 mg febuxostat twice daily, 87.5% of patients receiving 40/80 mg febuxostat once daily, and 78.1% of patients receiving placebo. TEAEs most frequently involved the categories of renal failure and impairment and renal function analyses. Conclusion Febuxostat proved to be efficacious in serum UA reduction and was well tolerated in gout patients with moderate‐to‐severe renal impairment. Patients randomly assigned to receive febuxostat demonstrated significantly lower serum UA levels and no significant deterioration in renal function.
  • Publisher: United States: Wiley Subscription Services, Inc
  • Language: English
  • Identifier: ISSN: 2326-5191
    EISSN: 2326-5205
    DOI: 10.1002/art.39654
    PMID: 26894653
  • Source: MEDLINE
    Alma/SFX Local Collection
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait